Citi Downgrades PTC Therapeutics (PTCT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $63.04 +0.67%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
Citi analyst Joel Beatty downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $67.00 (from $67.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $53.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Argus Downgrades Alcoa (AA) to Hold
- Citi Downgrades Motiva Infraestrutura (MOTV3:BZ) to Neutral
- Thermo Fisher Scientific (TMO) PT Raised to $800 at Citi
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
